Leila Akkari herself spoke about the tumour microenvironment in the context of liver cancer evolution, with Serena Vegna delcing deeper into genetic differences affecting the TME

In HCC, eIF3f|ACSL4 was shown to promote tumour malignancy by promoting fatty acid biosynthesis, with its targeting increasing anti-PD-1 efficacy

👉https://www.journal-of-hepatology.eu/article/S0168-8278(25)00206-5/fulltext

@jhepatology.bsky.social

In a related topic, more about MASLD in an amazing Nature Reviews Disease Primers article just published:

🔗 nature.com/articles/s41...

@jvlazarus.bsky.social

& just published in @jhepatology.bsky.social

🧬Mitochondrial CMPK2 is upregulated in human & experimental MASH
📈Ensues disease progression through the Nlrp3 inflammasome & pyroptosis
💉Nordihydroguaiaretic acid is a novel CMPK2 inhibitor supressing MASH

📰 doi.org/10.1016/j.jh...

Another great study, this time by Jerôme Eeckhoute: what drives hepatocyte-cholangiocyte transdifferentiation?

🔎 One requirement appears to be relieving epigenetic repression of cholangiocyte genes in hepatocytes ❗️

Agree! 👌🏼 Very interesting also to see several recent studies clustering patients based on extrahepatic complications and how this may help prognosis